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Introduction
Des pite substantial progress in the treatment of breast cancer, 
advanced disease is incurable and the goals of therapy consist of 
prolonging survival where possible but, most importantly, palliating 
symptoms and optimizing quality of life (QoL) [1–3]. Multiple 
parameters influence treatment choices for patients with metastatic 
breast cancer (MBC), including tumor biology, extent of disease, 
previous therapies, age, performance status, comorbidities, patient 
preference, and drug availability [1,2].
The role for oral chemotherapy in MBC was explored in two 
discussion forums held in San Antonio in December 2014 and 
December 2015. An expert faculty of breast medical oncology 
thought leaders and clinical experts from across Europe were invited 
to each interactive workshop to review the chemotherapy options 
for MBC and the potential role of oral cytotoxic agents in providing 
effective palliation. In addition to discussion around didactic state 
of the art presentations from the authors, the attendees discussed 
the management of case scenarios to help identify the place of 
oral chemotherapy in MBC. The following is a summary of these 
discussions and highlights important considerations in selecting 
oral chemotherapeutic agents for the management of patients with 
MBC. Support for both discussion forums and this manuscript was 
provided by an unrestricted educational grant from Pierre Fabre 
Medicament. The views expressed are those of the authors and were 
not influenced by the company.
Current therapeutic landscape for metastatic breast cancer
The ESO-ESMO 2nd international consensus guidelines for 
advanced breast cancer (ABC2) recommend that treatment choice 
is driven by many factors, such as biology (hormonal receptor 
and HER2 expression), patient characteristics (age, comorbidities, 
menopausal status), and patient preferences, among others [1,2]. 
For triple-negative breast cancer (TNBC) lacking therapeutic targets, 
chemotherapy is the mainstay of treatment [1,2]. Decisions regarding 
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A B S T R A C T
Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from 
multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs 
disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent 
chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option 
for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral 
chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in 
patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single 
agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is 
preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy 
also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression 
through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a 
strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in 
the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important 
considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.
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optimal selection, sequencing, and duration of therapy for patients 
with advanced breast cancer continue to evolve. For those with 
HER2-positive disease, HER2 blockade is the backbone of treatment. 
Combination strategies with HER2-targeted agents are most often 
employed, such as combinations with IV or oral chemotherapy or 
endocrine therapy [1,2,4].
In patients with endocrine-sensitive, HER2-negative disease, 
endocrine therapy alone is preferred with increasing options for 
both sequential endocrine treatments alone and in combination 
with targeted agents such as everolimus [1,2] and (at the time of this 
discussion forum only in the United States) palbociclib [5]. However, 
endocrine resistance typically occurs and nearly all patients will 
receive chemotherapy during the disease course [1,2]. Resistance 
to endocrine therapy has lacked a clear definition, complicating 
treatment decisions in this patient subset. The ABC2 consensus 
guidelines define primary endocrine resistance as a relapse while on 
the first 2 years of adjuvant endocrine therapy, or progressive disease 
within the first 6 months of first-line endocrine therapy for MBC 
while on endocrine therapy [1,2]. Secondary (acquired) endocrine 
resistance is defined as a relapse while on adjuvant endocrine 
therapy but after the first 2 years, or a relapse within 12 months 
of completing adjuvant endocrine therapy, or progressive disease at 
least 6 months after initiating endocrine therapy for MBC while still 
on endocrine therapy. Chemotherapy should be considered when 
there is concern regarding endocrine resistance and for those with 
immediately life-threatening and/or highly symptomatic disease. 
Numerous chemotherapeutic agents have demonstrated efficacy 
in patients with HER2-negative MBC, including oral agents and 
formulations [3].
Chemotherapy in metastatic breast cancer: considerations for therapy 
selection, sequencing, and duration
While the treatment of MBC is primarily palliative, strategies 
to optimize therapy and prolong survival remain important [1–3]. 
MBC is quite sensitive to chemotherapy, but with a large variation 
in the probability of response according to treatment factors and 
patient and disease features. Although duration of treatment and 
response often diminish as the number of lines of therapy increase, 
many patients will respond to multiple lines of chemotherapy well 
beyond the first-line regimen [6,7]. However, uncertainty remains 
regarding the best sequence of therapies as well as the optimal 
duration of therapy.
Meta-analyses and review of randomized clinical trial data 
demonstrate comparable efficacy, including overall survival (OS), 
for sequential versus combination chemotherapy [8,9]. In addition, 
sequential single-agent chemotherapy is associated with fewer 
adverse events, which can positively impact QoL. Based on similar 
efficacy, with better tolerability and QoL, current guidelines state 
that sequential single-agent chemotherapy is preferred over combi-
nation chemotherapy [1–3]. However, because combi nation 
regimens are associated with more rapid and higher proba-
bility of objective response, they may be needed for patients 
with rapidly progressing or life-threatening disease or highly 
symptomatic metastases.
Chemotherapy treatment selection should be based on previous 
chemotherapy exposure and response, side effect profile, comorbid 
conditions, and patient preference [1,2]. Chemotherapy selection 
is currently not tailored to tumor molecular profiles [1–3], with 
the possible exception of platinum agents for BRCA-associated 
cancers [1,2,10]. Numerous chemotherapeutic agents are available 
and have demonstrated efficacy in MBC, but there are few data 
from randomized clinical trials to advise on optimal sequencing of 
agents and this will be influenced by the use and type of adjuvant 
chemotherapy the patient has previously received, the treatment 
free interval and patient preferences [1–3]. Many patients will 
have received adjuvant anthracyclines with or without a taxane. 
Although patients with MBC may be rechallenged with an alternative 
anthracycline-based regimen if there is a long disease-free interval, 
different classes of agents are often preferred [1,2]. Taxanes remain 
an important first-line therapy for MBC in patients who are 
taxane-naïve or have disease progression more than 12 months 
after completion of adjuvant therapy with many clinicians using a 
different taxane or schedule to that used in the adjuvant setting.
Alternative choices for first-line therapies, and endorsed by the 
ABC2 guidelines [1,2], include single-agent capecitabine, vinorelbine, 
or eribulin. Specifically, eribulin demonstrated a survival benefit 
over the physicians’ treatment of choice in heavily pretreated 
patients with MBC in the phase III EMBRACE trial (median OS 13.1 
vs 10.6 months, hazard ratio [HR] 0.81; P = 0.041) [11]. A phase III 
study directly comparing eribulin to capecitabine as first-, second-, 
or third-line therapy in patients with anthracycline- and taxane-
pretreated MBC did not show superiority for eribulin, with similar 
median OS (15.9 for eribulin vs 14.5 months for capecitabine, HR 
0.88; P = 0.056) and progression-free survival (PFS: 4.1 vs 4.2 months, 
HR 1.08; P = 0.30) for both agents [12]. Gemcitabine, liposomal 
anthracyclines, nab-paclitaxel, platinum agents, ixabepilone, and 
clinical trial enrollment represent other treatment options for 
advanced disease, although ixabepilone is not available outside the 
United States [1–3].
Chemotherapy duration and the use of maintenance therapy 
remains an area of debate among clinicians. Continuation of 
chemotherapy until disease progression, if well tolerated, should be 
considered when prolonged disease control may be beneficial [1–3]. 
This is supported by data from a meta-analysis showing that a longer 
duration of first-line chemotherapy resulted in a significant PFS 
benefit (HR 0.64; P < 0.001) and OS (HR 0.91; P = 0.046) compared 
to shorter chemotherapy schedules [13]. However, given the modest 
improvement in OS, prolonged exposure to chemotherapy should be 
balanced against adverse events and QoL. Short breaks and flexibility 
in treatment schedule should also be considered for selected 
patients in remission [1–3]. Maintenance chemotherapy usually 
consists of continuing the same treatment dose and schedule until 
disease progression [14]. However, switch maintenance strategies 
are also under investigation and may improve OS and/or PFS, as 
demonstrated in the recent phase III IMELDA and TANIA trials of 
bevacizumab with or without chemotherapy [15,16]. For those with 
hormone receptor–positive breast cancer, maintenance endocrine 
therapy can be utilized after response to initial chemotherapy [17,18]. 
Ongoing studies are also exploring alternative dosing strategies, 
including metronomic dosing strategies, which are discussed in 
further detail below [19].
The role for oral chemotherapy in metastatic breast cancer
The concept that MBC is a treatable but still generally incurable 
disease reinforces the importance of balancing disease control 
with the detrimental effects that can be associated with prolonged 
chemotherapy exposure and very limited survival benefit [3]. Thus, 
it is important to discuss all treatment options with patients with 
MBC and evaluate the risk-to-benefit ratio, reflecting the treatment 
goals of improving both length and quality of life [1–3]. The needs 
of the patient and their personal preferences and expectations 
are important factors in treatment selection and acceptance 
of a therapeutic plan. Alternative dosing schedules and more 
convenient routes of administration, such as oral agents, should 
be considered, while ensuring that treatment is associated with 
low levels of cumulative toxicity. Numerous oral therapies are now 
available for the treatment of MBC, including chemotherapeutic 
agents and targeted agents. While oral targeted therapies such 
as lapatinib, everolimus, and palbociclib are improving patient 
outcomes, detailed discussion of these agents is beyond the scope 
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of this manuscript, which focuses specifically on the role for oral 
chemotherapies in MBC.
In comparison to standard intravenous (IV) chemotherapy, oral 
chemotherapy provides patients with more convenience and allows 
clinicians to more easily tailor therapy dosing if needed [20]. In 
addition, less time in the clinic is required, which translates into 
cost and staffing savings. Surveys demonstrate that most patients 
prefer oral therapy to IV treatments when equivalent efficacy is 
established [21,22]. However, oral chemotherapy is not free from 
potentially dangerous side-effects, and so it is essential from a 
safety perspective to have effective patient education and follow-
up, as well as simple dosing schedules [20]. Dosing mistakes, such as 
patients forgetting the treatment breaks commonly used with some 
therapies (i.e., 2 weeks on, 1 week off for capecitabine) or taking 
the wrong number of pills can negatively affect both efficacy and 
tolerability. Adherence can be a concern and is influenced by multiple 
factors, including complex treatment regimens, requirement for 
substantial behavioral changes, inconvenient or inefficient clinics, 
poor communication by healthcare providers, gastrointestinal 
side-effects or abdominal pathology, and history of mental illness 
[23,24]. Improper handling or storage of oral medications can also 
be a problem, compromising the effectiveness of the medication 
[25]. Providing continuous patient education throughout the 
treatment course can help prevent these issues and improve 
efficacy, QoL, and compliance.
Both capecitabine and vinorelbine have demonstrated con-
sider able efficacy and tolerability in MBC, particularly as second-
line and third-line therapy after taxane failure. Capecitabine has 
demonstrated efficacy in multiple phase III trials, while the data 
supporting oral vinorelbine is currently limited to phase II studies 
[26,27]. A systematic review of over 2000 patients pretreated with 
anthracyclines and taxanes who received single-agent chemotherapy 
with capecitabine or IV vinorelbine supported the efficacy of these 
chemotherapeutic agents, producing mean disease control rates 
(overall response plus stable disease) of approximately 55% and 50%, 
respectively [28].
As a single-agent, capecitabine has yielded median PFS or time to 
progression (TTP) ranging from 3.0 months to 7.9 months in patients 
with MBC (Table 1) [29–40]. In a recent review of 31 studies of oral 
vinorelbine in over 1000 patients with MBC, this agent demonstrated 
good efficacy and tolerability, both as monotherapy and in 
combination with capecitabine or targeted therapy [27]. As a single-
agent, oral vinorelbine was associated with a median PFS or TTP of 
4.0 months to 8.2 months (Table 2) [27,41–46]. The combination of 
oral vinorelbine with capecitabine is also effective, yielding median 
PFS or TTP ranging from 3.4 to 10.5 months in patients with MBC 
(Table 3) [27,47–54]. There is no direct comparison between the use 
of these two agents in combination as opposed to in sequence. The 
combination is more complex, related to a significant incidence of 
side effects, and should be reserved for selected cases (e.g., highly 
symptomatic patients). Based on the available data, the current 
ABC2 guidelines identify single-agent capecitabine, vinorelbine, or 
eribulin as the preferred choices for patients who have previously 
received anthracyclines and taxanes and do not require combination 
chemotherapy [1,2].
In patients with HER2-positive MBC, both capecitabine and 
IV vinorelbine have demonstrated efficacy and tolerability in 
combination with HER2-targeted agents. Capecitabine is effective 
in combination with trastuzumab and lapatinib, with median 
TTP of 8.2 months and 6.2 months, respectively in patients with 
HER2-positive MBC after progression on first-line trastuzumab 
and chemotherapy [55,56]. Intravenous vinorelbine has also 
demonstrated efficacy in HER2-positive disease, demonstrating 
similar or better response rates and median TTP than taxanes when 
combined with trastuzumab as first-line chemotherapy in the phase 
III TRAVIOTA and HERNATA trials (Table 4) [57,58]. Additionally, in 
a retrospective comparison of two case series, oral vinorelbine in 
combination with trastuzumab appeared to be at least as effective as 
a standard taxane and trastuzumab combination [59]. The efficacy 
associated with vinorelbine plus trastuzumab, together with a good 
tolerability profile, makes this combination an important option for 
the treatment of HER2-positive MBC. Promising phase II data also 
exist for the safety and activity of the combination of vinorelbine 
with both trastuzumab and pertuzumab [60].
Metronomic chemotherapy in metastatic breast cancer
The tolerability and convenience of oral chemotherapy makes 
it an ideal formulation for metronomic dosing approaches. 
Metronomic chemotherapy consists of frequent administration 
of chemotherapy (often daily) at individual doses well below the 
maximum tolerated dose (MTD) without prolonged drug-free 
Table 1
Selected studies of capecitabine as a single agent in metastatic breast cancer [30–40]
   Line of ORR,  CBR,  PFS/TTP,  OS, 
Reference Capecitabine schedule N treatment % % months months
O’Shaughnessy et al. Ann Oncol 2001 [30] 1255 mg/m2 bid d1-14 q3w 61 1st 30 81 4.1 19.6
Stockler et al. J Clin Oncol 2011 [31] 1000 mg/m2 bid d1-14 q3w or  214 1st 21 49 6.0 22
 650 mg/m2 bid continuously
Kaufmann et al. Eur J Cancer 2010 [32] 1000 mg/m2 bid d1-14 q3w 161 1st 26.1 64 7.9 18.6
Robert et al. J Clin Oncol 2011 [33] 1000 mg/m2 bid d1-14 q3w 206 1st 23.6 NR 5.7 NR
Sparano et al. J Clin Oncol 2010 [34] 1250 mg/m2 bid d1-14 q3w 612 1st, 2nd, or 3rd,  28.8a 68.2a 4.4b 15.6
   post anthrax and txn
Talbot et al. Br J Cancer 2002 [35] 1255 mg/m2 bid d1-14 q3w 22 2nd 36 59 3.0 7.6
Brufsky et al. J Clin Oncol 2011 [36] 1000 mg/m2 bid d1-14 q3w 47 2nd 15.4 NR 4.1 NR
Miller et al. J Clin Oncol 2005 [37] 1250 mg/m2 bid d1-14 q3w 230 2nd or 3rd,  9.1 NR 4.17 14.5
   post anthrax and txn
Reichardt et al. Ann Oncol 2003 [38] 1250 mg/m2 bid d1-14 q3w 136 2nd or later,  15 62 3.5 10.1
   post anthrax and txn
Blum et al. J Clin Oncol 1999 [39] 1255 mg/m2 bid d1-14 q3w 163 2nd or later,  20 60 3.1 12.8
   txn refractory
Blum et al. Cancer 2001 [40] 1255 mg/m2 bid d1-14 q3w 75 2nd or later,  26 57 3.2 12.2
   txn refractory
aN = 462; bN = 480
Abbreviations: anthra, anthracycline; bid, twice daily; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free 
survival; q3w, every 3 weeks; TTP, time to progression; txn, taxane
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breaks [61,62]. This approach offers several advantages, including 
low economic costs, oral administration, good tolerability, positive 
patient perception, and efficacy based on data from phase II and 
phase III clinical trials [63].
The mechanisms of action for metronomic chemotherapy 
are multi-targeted and remain to be fully elucidated. Possible 
mecha nisms of action include inhibition of angiogenesis, stimu-
lation of the immune system, and direct targeting of tumor 
cells (Figure 1) [61]. The antiangiogenic effects associated with 
metronomic chemotherapy are attributed to numerous mechanisms, 
such as direct targeting of tumor neovasculature, increased 
expression of the angiogenic inhibitor thrombospondin-1 [64], 
induction of apoptosis in circulating endothelial cells, and blockade 
of endothelial progenitor cell mobilization from the bone marrow 
[61,65–67]. Metronomic chemotherapy can also augment the anti-
tumor immune response through a number of complex mechanisms. 
For instance, metronomic administration of chemotherapy stimu-
lates apoptosis of immunogenic cells, depletion of regulatory T cells, 
Table 2
Oral vinorelbine as a single agent in metastatic breast cancer [27,41–46]
   Line of ORR,  CBR,  PFS/TTP,  OS, 
Reference Oral vinorelbine schedule N treatment % % months months
Freyer et al. J Clin Oncol 2003 [41] 80 mg/m2 weekly  58 1st 31 62 4.2 Not
 (after 3 administrations at 60 mg/m2)       reached
Amadori et al. ECCO 2001 [27,42] 80 mg/m2 weekly  63 1st 27 NR 4.6 21
 (after 3 administrations at 60 mg/m2)
Bartsch et al. ESMO 2008 [27,43] 60 mg/m2 d1,8 q3w 100 1st - 4th Post anthra 25 51 7 17
Blancas et al. ASCO 2010 [27,44] 60 mg/m2 weekly  45 1st or 2nd 29.5 59 4 NR
Mansour et al. ICACT 2010 [27,45] 80 mg/m2 d1,8 q3w  26 1st Post anthrax 42 NR 5 NR
 (after 1 cycle at 60 mg/m2)  and/or txn
Steger et al. ESMO 2014 [46] 80 mg/m2 weekly  70 1st (bone mets) NR 55.7 8.2 NR
 (after 4 administrations at 60 mg/m2)
Abbreviations: anthra, anthracycline; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; q3w, 
every 3 weeks; TTP, time to progression; txn, taxane
Table 3
Oral vinorelbine in combination with capecitabine in metastatic breast cancer [27,47–54]
 Oral vinorelbine +   Line of ORR,  CBR,  PFS/TTP,  OS, 
References capecitabine schedule N treatment % % months months
Tubiana-Mathieu et al. BJC 2009 [47] OV 80 mg/m2 d1,8  55 1st 51 63 8.4 29
 (after 1st cycle at 60 mg/m2)
 CAP 2000 mg/m2/d1-14, q3w
Nolè et al. Cancer Chemother Pharmacol  OV 60 mg/m2 d1,8,15 52 1st 44.2 73.1 8.4 25.8
2009[48] CAP 2000 mg/m2/d1-14, q3w
Campone et al. Breast J 2013 [49] OV 80 mg/m2 d1,8  44 1st Post anthra 31.8 70.5 7.2 22.2
 CAP 2000 mg/m2/d1-14, q3w
Tawfik et al. Cancer Chemother  OV 60 mg/m2 d1,8 28 1st Post anthra 57.1 76.5 8.6 27.2
Pharmacol 2013 [50]  CAP 2000 mg/m2 d1-14, q3w  and/or txn
Finek et al. Anticancer Res 2009 [51] OV 60 mg/m2 d1,8  115 1st or 2nd Post anthra 56.5 87.8 10.5 17.5
 CAP 2000 mg/m2/d1-14, q3w
Delcambre et al. SABCS 2005 [52] OV 60 mg/m2 d1,8  31 1st: 90%  61 NR NR NR
 CAP 2500 mg/m2/d1-14, q3w  2nd: 10%
Jones et al. Cancer Chemother  OV 60 mg/m2 d1,8,15 40 Post anthra and txn 20.0 62.5 3.4 11.3
Pharmacol 2010 [53] CAP 2000 mg/m2/d1-14, q3w
Lorusso et al. Ann Oncol 2006 [54] OV 60 mg/m2 d1,8  38 Post anthra and txn 39.4 76.3 4.5 10.0
 CAP 2000 mg/m2/d2-7 and 9-16, q3w
Abbreviations: anthra, anthracycline; CAP, capecitabine; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; OS, overall survival; OV, oral vinorelbine; 
PFS, progression-free survival; q3w, every 3 weeks; TTP, time to progression; txn, taxane
Table 4
Phase III TRAVIOTA and HERNATA trials of first-line vinorelbine with HER2-targeted therapy [57,58]
 TRAVIOTA [57] HERNATA [58]
 Taxane/Tras VNR IV/Tras  Docetaxel/Tras VNR IV/Tras 
N 40 41  143 141 
ORR, % 40 51 P = 0.37 59.3 59.3 P = 1.00
CBR, % 58 66 NR 75.6 75.4 NR
Median TTP, months 6.0 8.5 P = 0.9 12.4 15.3 HR 0.94; 
      P = 0.67
Median TTF, months 4.7 5.8 P = 0.15 5.6 7.7 HR 0.50; 
      P < 0.0001
Median OS, months NR NR NR 35.7 38.8 HR 1.01; 
      P = 0.98
Abbreviations: CBR, clinical benefit rate; HR, hazard ratio; NR, not reported; ORR, overall response rate; OS, overall survival; Tras, trastuzumab; TTF, time to treatment 
failure; TTP, time to progression; VNR IV, vinorelbine administered intravenously
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and increased antigen presentation through maturation of dendritic 
cells. Data also suggest direct targeting of tumor initiating cells or 
cancer stem cells [61] and inhibition of hypoxia-inducible factor 1 
(HIF-1) [68] as additional mechanisms of action for metronomic 
chemotherapy, as reviewed elsewhere [63,69]. There is significant 
crosstalk between these various mechanisms of action, providing 
a rationale for combinations of metronomic chemotherapy with 
targeted agents or immunotherapies [61].
Interestingly, preclinical data suggest tumors that acquire 
resistance to metronomic chemotherapy, such as low-dose cyclo-
phosphamide, retain their sensitivity to MTD cyclophosphamide 
[61,70]. This is important because it suggests metronomic chemo-
therapy and MTD chemotherapy could essentially be thought of 
as two distinct drugs and development of resistance to one may 
not preclude the use of the same drug using an alternative dosing 
schedule. Moreover, metronomic chemotherapy may prevent or 
delay development of chemotherapy resistance [61]. In mouse 
models of ovarian cancer, intermittent administration of docetaxel 
resulted in significant upregulation of genes involved in docetaxel 
resistance, while continuous dosing did not upregulate these genes 
[71]. Further clinical studies are needed to fully understand the 
impact of metronomic chemotherapy on drug resistance.
Numerous phase II clinical trials have demonstrated activity 
for oral chemotherapeutic agents as metronomic monotherapy in 
patients with MBC (Table 5) [31,63,72–75]. First-line capecitabine, 
administered at standard doses or continuously, improved OS (22 
vs 18 months; HR 0.72; P = 0.02) and was better tolerated than 
classical cyclophosphamide, methotrexate, and fluorouracil (CMF) 
in women with MBC unsuitable for more intensive chemotherapy 
regimens [31]. Another phase II study of metronomic capecitabine 
(1500 mg once a day) demonstrated a clinical benefit rate (CBR) of 
62%, including activity in patients with heavily pretreated disease 
and those who had previously received standard dose capecitabine 
[72]. Metronomic capecitabine was well tolerated, with minimal 
grade 3 and no grade 4 adverse events reported. However, another 
phase II randomized noninferiority trial was unable to demonstrate 
noninferiority for continuous dosing of capecitabine at 800 mg/m2 
bid daily compared to standard dosing (1250 mg/m2 bid days 1 to 
14 every 21 days) with regards to disease progression at 1 year [73].
Metronomic oral vinorelbine has demonstrated promising 
activity and safety as a single agent. Phase I trials established the 
recommended dose for metronomic oral vinorelbine as 50 mg 3 times 
per week for 3 weeks on, 1 week off [76,77]. In a clinical trial of 34 
elderly patients with MBC, first-line metronomic oral vinorelbine 
dosed at 70 mg/m2 resulted in an objective response in 38% of 
patients and was associated with a disease control rate of 68% [74]. 
Median PFS and OS were 7.7 months and 15.9 months, respectively. 
This active regimen was also well tolerated with no grade 4 adverse 
events and few grade 3 events, the most common of which were 
neutropenia (9%), anemia (9%), and febrile infection (6%). A second 
study of metronomic oral vinorelbine (30 mg, one day on and one 
day off) in elderly patients with MBC demonstrated a CBR ≥6 months 
of 50% and a disease control rate of 87.4% [75]. Excellent tolerability 
was observed, with improved QoL after 6 months of therapy and no 
grade 3/4 adverse events reported. The ongoing phase II randomized 
TEMPO-Breast 01 trial is comparing standard dose oral vinorelbine 
to metronomic oral vinorelbine as first-line therapy in patients with 
hormone receptor–positive, HER2-negative MBC [78]. Trial results 
are expected in 2017.
Combination metronomic regimens have also demonstrated 
activity and excellent tolerability in MBC (Table 6) [63,79–92]. The 
first metronomic combination to be explored in the metastatic 
setting was cyclophosphamide plus methotrexate (CM) [63]. A 
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Fig. 1. Potential mechanisms of action of metronomic chemotherapy [61]. Reprinted 
by permission from Macmillan Publishers Ltd: Nat Rev Clin Oncol 2014;11:413-31. 
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Table 5
Selected trials of metronomic oral chemotherapy monotherapy in advanced breast cancer [31,72–75]
   Line of ORR,  CBR,  PFS/TTP,  OS, 
References Agents and schedule N treatment % % months months
Stockler et al. J Clin Oncol 2011 [31] Capecitabine  107 1st 20 50 6 NR
 (650 mg/m2 bid continuously)
Fedele et al Eur J Cancer 2012 [72] Capecitabine  58 2nd or later 24 62 7 17
 (1500 mg daily continuously)
Martin et al. Oncologist 2015 [73] Capecitabine  97 1st – 3rd 32 71.2 6.8 23.3
 (800 mg/m2 bid continuously)
Addeo et al. Clin Breast Can 2010 [74] Oral vinorelbine  34 1st (elderly) 38 68 7.7 15.9
 (70 mg/m2 weekly fractionated on 
 days 1, 3, and 5 for 3 weeks on, 
 1 week off)
De Iuliis et al. Tumori 2015 [75] Oral vinorelbine  32 1st – 3rd (elderly) 68.7 87.4a 9.2 NR
 (30 mg one day on, one day off)
aDisease control rate; CBR ≥6 months was 50%
Abbreviations: bid; twice daily; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; 
TTP, time to progression
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study of metronomic CM in 63 patients with MBC demonstrated 
an ORR and CBR of 19% and 32%, respectively [79]. Longer follow-
up of this combination in a larger group of patients with MBC 
(N = 153) demonstrated prolonged clinical benefit of 12 months 
or more in 16% of patients [80]. A trial of metronomic CM with or 
without thalidomide in 171 patients with MBC exhibited an ORR of 
20.9% and CBR of 41.5% in the 90 patients who received CM [81]. 
No improvement was observed with the addition of thalidomide. 
Likewise, a retrospective trial that included 39 patients who received 
metronomic CM for MBC demonstrated an ORR of 20% and a tumor 
growth control rate of 51% [82].
The all-oral combination of metronomic vinorelbine and cape-
citabine has also demonstrated activity in MBC. The phase I/
II VICTOR-1 trial examined vinorelbine (40 mg on days 1, 3, and 
5 weekly) with capecitabine (500 mg thrice daily) in patients 
with MBC and demonstrated a response rate of 16.1% and a CBR 
of 58.1% [83]. The combination was well tolerated, with only 9 
total grade 3/4 adverse events reported, consisting primarily 
of hematologic events, neuropathy, and hand-foot syndrome. 
The multicenter phase II VICTOR-2 study further examined the 
combination of metronomic oral vinorelbine and capecitabine 
in MBC, demonstrating a CBR of 80%, minimal grade 3/4 adverse 
events, and no deterioration of QoL [84].
In the phase II VEX trial, the combination of metronomic oral 
vinorelbine, cyclophosphamide, and capecitabine resulted in a 
CBR of 85% in previously untreated patients and 72% in pretreated 
patients with hormone receptor–positive MBC [85]. Only 4% of 
patients experienced a grade 3 adverse event (hand-foot syndrome, 
hematologic toxicity, and liver toxicity) and no grade 4 events 
were reported. Ongoing phase II and phase III clinical trials are 
exploring metronomic oral capecitabine or vinorelbine, including 
in the neoadjuvant setting with endocrine therapy and as first-line 
maintenance therapy in patients with response or stable disease 
following initial chemotherapy [63]. Studies are also demonstrating 
efficacy for metronomic oral chemotherapy in combination with 
targeted therapies such as antiangiogenic agents (Table 6) [63,89–92].
Conclusions
Balancing efficacy and QoL is essential for patients with MBC [1,2]. 
Selection of chemotherapy, endocrine therapy, and targeted agents 
should be based on current treatment recommendations, clinical 
trial data, careful assessment of patient and disease characteristics, 
and very importantly, patient preferences. Sequential monotherapy 
is the preferred choice for the vast majority of patients who 
require chemotherapy. Optimal strategies for sequencing therapy 
Table 6
Selected trials of metronomic oral chemotherapy combinations in advanced breast cancer [79,81,83–92]
   Line of ORR,  CBR,  PFS/TTP,  OS, 
Reference Agents and schedule N treatment % % months months
Combination oral chemotherapy regimens
Colleoni et al.  Cyclophosphamide (50 mg/day continuously) +  63 1st or later 19.0 31.7 2.8 NR
Ann Oncol 2002 [79] methotrexate (2.5 mg bid days 1 and 2 weekly)
Colleoni et al.  Cyclophosphamide (50 mg/day continuously) + 90 1st or later 20.9 41.5 3.8 18.2
Ann Oncol 2006 [81] methotrexate (2.5 mg bid days 1 and 4 weekly)
VICTOR-1 Cazzaniga et al  Vinorelbine (20-40 mg daily, d1,3,5 weekly) +  31 1st or later 16.1 58.1 NR NR
Int J Breast Cancer 2014 [83] capecitabine (500 mg tid continuously)
VICTOR-2 Cazzaniga et al Vinorelbine (40 mg daily, d1,3,5 weekly) +  85 1st or later NR 80 NR NR
ABC3 2015 [84] capecitabine (500 mg tid continuously)
VEX trial Montagna et al  Vinorelbine (40 mg daily, d1,3,5 weekly) +  69 1st or later 30.4 78.3 22 for NR
Eur J Cancer 2015 [85] capecitabine (500 mg tid continuously) +      untreated
 cyclophosphamide (50 mg daily)      patients; 
      14 for 
      pretreated 
      patients 
Addeo et al Cancer Chemother  Vinorelbine (70 mg/m2 daily, d1,3,5 weekly) +  36 1st or later, 52 77 8 11
Pharmacol 2012 [86] temozolomide (75 mg/m2 d1-21 q4w)   untreated brain mets
Wang et al Cancer Chemother  Capecitabine (1000 mg/m2 bid) +  66 1st – 5th 30.3 53.0 5.2 16.9
Pharmacol 2012 [87] cyclophosphamide (65 mg/m2 daily) 
 days 1-14 q3w
Yoshimoto et al Cancer  Capecitabine (828 mg/m2 bid) +  45 1st or 2nd 44.4 57.8 12.3 Not
Chemother Pharmacol 2012 [88] cyclophosphamide (33 mg/m2 bid)       reached
 days 1-14 q3w
Combinations with targeted agents
Orlando BMC Cancer 2006 [89] Cyclophosphamide (50 mg daily) +  22 1st or later 18 46 6 NR
 methotrexate (2.5 mg bid, days 1 and 4 weekly) + 
 trastuzumab (6 mg/kg q3w)
Dellapasqua et al Capecitabine (500 mg tid continuously) +  46 1st or later 48 68 10.5 NR
J Clin Oncol 2008 [90] cyclophosphamide (50 mg daily) + 
 bevacizumab (10 mg/kg q2w)
Garcia-Saenz et al Cyclophosphamide (50 mg daily) +  22 2nd or later 31.8 63.6 7.5 13.6
J Chemother 2008 [91] methotrexate (1 mg/kg q2w) + 
 bevacizumab (10 mg/kg q2w)
Saloustros et al Vinorelbine (50 mg 3 times a week) +  13 1st or later 7.7 53.8 NR NR
J BUON 2011 [92] bevacizumab (10 mg/kg q2w)
Abbreviations: bid; twice daily; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; q2w, every 2 
weeks; q3w, every 3 weeks; q4w, every 4 weeks; tid, thrice daily; TTP, time to progression
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are currently unknown. Chemotherapy should be continued until 
disease progression as long as it is well tolerated.
Within the landscape of treatment options, increased attention 
to patient preference and QoL favors the use of oral chemotherapy 
agents, such as capecitabine and oral vinorelbine [20]. These agents 
prolong disease control, provide good tolerability, and reduce 
the time and cost associated with treatment. However, patient 
education is fundamental to ensuring appropriate safe use of oral 
chemotherapeutic agents [20,23]. Oral chemotherapy is also a 
good option for maintenance treatment to prolong disease control. 
Metronomic chemotherapy provides multiple-targeted action 
against breast tumor progression [61]. The convenience and low cost 
of oral chemotherapeutic agents makes them ideal for metronomic 
dosing strategies [63]. Metronomic chemotherapy approaches, 
such as cyclophosphamide ± methotrexate, capecitabine, and oral 
vinorelbine, have demonstrated efficacy and excellent tolerability in 
phase II trials and can be considered for some patients with advanced 
disease [19,63]. Results from large, randomized clinical trials are 
needed to fully understand the optimal role and positioning for 
metronomic approaches in the management of patients with MBC.
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